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Large-scale DNA databanks linked to electronic medical record (EMR) systems have been proposed as an approach for rapidly generating
large, diverse cohorts for discovery and replication of genotype-phenotype associations. However, the extent to which such resources are
capable of delivering on this promise is unknown. We studied whether an EMR-linked DNA biorepository can be used to detect known
genotype-phenotype associations for ﬁve diseases. Twenty-one SNPs previously implicated as common variants predisposing to atrial
ﬁbrillation, Crohn disease, multiple sclerosis, rheumatoid arthritis, or type 2 diabetes were successfully genotyped in 9483 samples
accrued over 4 mo into BioVU, the Vanderbilt University Medical Center DNA biobank. Previously reported odds ratios (ORPR) ranged
from 1.14 to 2.36. For each phenotype, natural language processing techniques and billing-code queries were used to identify cases
(n ¼ 70–698) and controls (n ¼ 808–3818) from deidentiﬁed health records. Each of the 21 tests of association yielded point estimates
in the expected direction. Previous genotype-phenotype associations were replicated (p< 0.05) in 8/14 cases when the ORPR was> 1.25,
and in 0/7 with lower ORPR. Statistically signiﬁcant associations were detected in all analyses that were adequately powered. In each of
the ﬁve diseases studied, at least one previously reported association was replicated. These data demonstrate that phenotypes represent-
ing clinical diagnoses can be extracted from EMR systems, and they support the use of DNA resources coupled to EMR systems as tools for
rapid generation of large data sets required for replication of associations found in research cohorts and for discovery in genome science.Introduction
The deployment of electronic medical record (EMR)
systems offers the hope of improving routine care, not
only by enhancing individual practitioner access to patient
information but also by aggregating information for clin-
ical research and quality improvement.1 EMRs and associ-
ated support systems can reduce medication errors, costs,
and inappropriate testing and improve quality of care,
physician documentation, and guideline adherence.2–8
Because EMRs contain large populations with diverse
diseases, they have the potential to act as platforms for
generating sets of cases and controls for clinical and
translational research. Potential advantages of such an
approach include rapid and inexpensive creation of large,
inclusive patient sets,9 as well as support for studies of
disease-disease or disease-drug interactions over time. An
especially appealing, albeit complex, vision is one in
which dense genomic information is accrued into EMRs,
ultimately enabling discovery and incorporation into prac-
tice of new genotype-phenotype associations.10–12
Implementing such a vision requires that major obstacles
be overcome, including technological, computational, ethi-
cal, and ﬁnancial issues, and determining whether genomic
information will meaningfully inform clinical decision
making and healthcare outcomes. An important hypothesis
to be tested13 is the idea that large biorepositories containing1Ofﬁce of Personalized Medicine, 2Center for Human Genetics Research, 3Ofﬁ
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challenges to augment or supplement traditional research
designs in which cases and controls are prospectively
enrolled and phenotype data are systematically collected.
BioVU, the Vanderbilt DNA databank,14 represents such
a biorepository. To test the utility of the resource in
addressing these challenges,we genotyped the ﬁrst ~10,000
samples accrued (over 4 mo) for SNP sites reproducibly
associated with a range of human diseases. Automated
queries were then developed, validated, and deployed for
the identiﬁcation of cases and controls in ﬁve common
diseases, andpreviously reported genotype-phenotype rela-
tionships were examined. Our results provide support for
the concept that biorepositories linked to ‘‘real-world’’
EMR data represent robust tools for accelerating genome-
driven diagnostics and therapeutics.Subjects and Methods
Inclusion and Exclusion Criteria
BioVU accrues DNA samples extracted from blood remaining from
routine clinical testing after the samples have been retained for
3 days and are scheduled to be discarded. A full description of
the resource and its ethical protections has been published else-
where.14 The resource contains data and tissues that are deidenti-
ﬁed in accordance with provisions of Title 45, Code of Federal
Regulations, part 46 (45 CFR 46) that deﬁne criteria force of Research, 4Department of Anesthesiology, 5Department of Biomedical
nd Biophysics, 8Department of Pharmacology, Vanderbilt University School
Genetics. All rights reserved.
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investigations that are considered ‘‘nonhuman subjects’’ research.
Exclusion criteria are as follows: poor-quality or insufﬁcient DNA,
age < 18 yrs, absence of a signed consent-to-treatment form,
a formal indication (on the consent-to-treatment form or else-
where) that an individual wishes to opt out, or duplicate samples.
In addition, a small percentage (~2%) of patients is randomly
excluded from BioVU so that it is not possible to know whether
any individual’s sample is or is not included in the biobank. The
project has been reviewed and approved at multiple levels,
including the institutional review board, internal and external
ethics committees, the community advisory board and the legal
department (Nashville, TN, USA), as well as the Federal Ofﬁce of
Human Research Protection (Washington, D.C., USA), and this
oversight is ongoing. As of March 22, 2010. the resource included
80,635 samples, with an accrual rate of ~500–700 per wk.
Phenotypes and Genotypes Analyzed
Our aim was to study SNPs previously and reproducibly associated
in GWASwith susceptibility to common diseases and to determine
whether those associations could be replicated with the use of
only the information derived from the EMR to determine case
and control status. The conditions chosen were atrial ﬁbrillation
(AF),15 Crohn disease (CD),16–18 multiple sclerosis (MS [MIM
126200]),19,20 rheumatoid arthritis (RA [MIM 180300]),16,21 and
type 2 diabetes (T2D [MIM 125853]), because there were several
single locus hits to replicate for each disorder and the diseases
varied in level of difﬁculty for the EMR phenotype abstrac-
tion.16,22–24 The assayed SNPs and their primer sequences are pre-
sented in Table S1, available online. We selected 21 SNPs that had
consistently shown replication for these diseases by late 2007; SNP
associations studied after this date were therefore not included.
The individuals studied were accrued in the ﬁrst 4 mo of operation
of the resource.
We selected this set of diseases and SNPs to ask the question of
whether EMR-derived phenotypes can be used for human
genetic-association studies. The previously reported odds ratios
(ORPR) for the SNPs that we examined ranged from 1.14 to 2.36.
Table S1 also presents power calculations25 performed in deter-
mining the sample size needed to replicate each ORPR at 80%
power, given reported allele frequencies in cases and controls for
each disease, for determining whether we were powered to detect
the selected effects.
Identifying Cases and Controls
For each disease, cases and controls were identiﬁed in the
Synthetic Derivative, a deidentiﬁed image of the EMR linked to
BioVU by anonymous research unique identiﬁers.14 The Vander-
bilt EMR began accumulating clinical data in the early 1990s
and now includes all inpatient and outpatient billing codes, labo-
ratory values, reports, and clinical documentation, almost all in
electronic formats available for searching. It currently contains
over 120 million documents on about 2 million patients.26 The
synthetic derivative is refreshedmonthly to add new clinical infor-
mation from the EMR as it is accrued.
For each disease, content experts (listed in Acknowledgments)
were consulted to develop algorithms that segmented the deidenti-
ﬁed EMR data into four groups: deﬁnite cases (algorithm-deﬁned);
possible cases (requiring manual curation); exclusions for match-
ing potentially overlapping diseases or symptoms or insufﬁcient
data for classifying; andcontrols (algorithm-deﬁned). The selection
algorithms are presented in the Appendix. In brief, cases were
selected via disease-speciﬁc combinations of billing codes, patientThe Amencounters, laboratory data, and natural language processing
(NLP) techniques on unstructured patient records such as medica-
tions, electrocardiograms, or past medical history. To deﬁne con-
trols, we adopted criteria to ensure that the diagnosis had been
sought and was absent. This generally included visits to primary
care or internal medicine clinics with nonempty ‘‘past medical
history’’ sections and medication lists. In addition, controls for
atrial ﬁbrillation all had electrocardiograms that didnot showatrial
ﬁbrillation. We also excluded potentially overlapping conditions,
such as other inﬂammatory arthritides from rheumatoid arthritis
controls and autoimmune diseases from rheumatoid arthritis,
multiple sclerosis, and Crohn disease controls.
Initial algorithms were developed to identify records from each
of the four classiﬁcations from the samples in the synthetic deriv-
ative, and the results were reviewed by two physicians not associ-
ated with algorithm development. The results of the manual
classiﬁcation were then used to improve the algorithms, and the
procedure was iterated until the positive predictive value (PPV)
reached designated targets of R 95% for deﬁnite cases and R
98% for controls. In each algorithm iteration, the physicians
reviewed a different set of 50 randomly selected cases and controls,
and the ﬁnal algorithm-performance numbers represent the
performance of the algorithm on a test set not previously reviewed
by either the algorithm developers or the physician reviewers.
The ﬁnal algorithms were then applied to the initial BioVU sample
set of 9483 subjects. Populations for cases and controls for
rheumatoid arthritis, Crohn disease, atrial ﬁbrillation, and type 2
diabetes were deﬁned exclusively by the ﬁnal algorithm. Each
phenotype algorithm was run on the full set of 9483 subjects
such that a particular person could be a case for one condition,
a control for one or more other conditions, or unknown for one
or more other conditions. Because of the low count of deﬁnite
and possible cases for multiple sclerosis, we tuned the multiple
sclerosis algorithm for sensitivity and the physician reviewers
manually reviewed the electronic records of all deﬁnite and
possible cases.
Data Analysis
Genotyping was conducted by the Vanderbilt DNA Resources Core
with the use of the midthroughput Sequenom genotyping plat-
form, based on a single-base primer extension reaction coupled
with mass spectrometry. Quality-control procedures included
examination of marker and sample genotyping efﬁciency, allele-
frequency calculations, and tests of Hardy-Weinberg equilibrium
(HWE). As described in Results, some SNPs poorly assayed on the
Sequenom platform (as indicated by deviations from HWE) were
regenotyped with TaqMan assays and the ABI Prism 7900HT
Sequence Detection System (Applied Biosystems).
Ancestry was derived from administrative data recorded in the
EMR; 9.2%of records did not include recorded ancestry or recorded
the ancestry as ‘‘unknown.’’ Accordingly, the data were analyzed
with respect to ancestry in twodifferentways. In theﬁrst, only cases
and controls that had ‘‘non-Hispanic white’’ (European American)
coded in the EMR were used, whereas in the second, records desig-
natedas either ‘‘non-Hispanicwhite’’ or ‘‘unknown’’were included.
Preliminary data directly examining ancestry-informative markers
in the BioVU ‘‘unknown’’ group indicate that>85%of cases cluster
with European Americans (Ritchie et al., poster presented as part of
the Illumina Technology Workshops at the ASHG 59th Annual
Meeting, Honolulu, HI, USA, October 22, 2009). Thus, we expect
that both the non-Hispanic white and the non-Hispanic white þ
unknown records are primarily European American.erican Journal of Human Genetics 86, 560–572, April 9, 2010 561
Figure 1. Identifying Cases and Controls
The numbers presented are for European
American subjects, with a deﬁnite diag-
nosis. Table S2 presents the numbers for
other groupings studied here.Single-locus tests of association (cases versus controls) were
conducted for each previously reported SNP. We calculated allelic
(chi-square) and genotypic (logistic regression) ORs and 95%
conﬁdence intervals (CIs) for dominant, additive, and recessive
genetic models. All statistical analyses were conducted in SAS,
version 9.1, with the use of two-tailed tests.Role of the Funding Source
The sponsor of the study had no role in study design, data collec-
tion, data analysis, data interpretation, writing of the report, or the
decision to submit for publication. The corresponding author had
full access to all the data in the study and had ﬁnal responsibility
for the decision to submit for publication.Results
Identifying Cases and Controls
The positive predictive values of case and control selection
algorithms were 97%–100%, except for multiple sclerosis,
in which algorithm-classiﬁed possible cases were also man-
ually reviewed because of small sample size (Table S2).
For the rheumatoid arthritis and multiple sclerosis pheno-
types, we identiﬁed both deﬁnite cases and deﬁnite cases
with other, potentially overlapping, autoimmune diseases
(‘‘probable cases’’): for rheumatoid arthritis, there were
174 deﬁnite cases of European ancestry and 346 deﬁnite þ
probable cases of European or unknown ancestry, and the
corresponding ﬁgures for multiple sclerosis were 70 and
124, respectively.
Figure 1 shows the distribution of cases and controls
across the ﬁve phenotypes analyzed. In the set of 9483
records analyzed by NLP for the ﬁve diseases, there were
1212 deﬁnite cases of European ancestry and 5114 con-
trols. There were 4072 that served as either a case or a
control in more than one analysis.
Genotyping
A total of 9483 samples were genotyped for 23 SNPs across
the ﬁve diseases with the use of the Sequenom platform.
We excluded 1847 samples with genotyping efﬁciency <
90% from data analysis. These failures were primarily
from the ﬁrst several plates processed and reﬂected the
fact that this was the ﬁrst set of DNA samples genotyped
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efﬁciency for individual SNPs varied
from 95.4%–100% (Table S3). The
number of deﬁnite cases of European
ancestry in which genotyping was
successful ranged from 61 (multiplesclerosis) to 510–533 (type 2 diabetes; depending on
the speciﬁc SNP), with 658–2884 controls (Table 1 and
Table S4).
Four SNPs were ﬂagged because of signiﬁcant deviations
from HWE at p < 0.05. Two of these (rs7901695 and
rs7903146), both in TCF7L2 (MIM 602228) and associated
with type 2 diabetes, are in linkage disequilibrium with
other markers studied here in the same gene (based on the
HapMap) and so were eliminated from further analysis.
One rheumatoid arthritis-associated SNP in theHLA cluster
on chromosome 6 (MIM 142860), rs6457617, could not be
successfully assayed with Sequenom or TaqMan. We there-
fore dropped this SNP and instead genotyped rs6457620 by
using a TaqMan assay (genotyping efﬁciency ¼ 99.46%;
HWE p value ¼ 0.26). The SNP rs6457620 is in complete
linkage disequilibriumwith rs6457617 (r2¼ 1) in the Inter-
national HapMap Project samples of European ancestry
(CEU).27 The fourth SNP, rs2200733, an atrial-ﬁbrillation-
associated variant, had low genotyping efﬁciency in
addition to deviation from HWE (p < 0.05). This SNP was
successfully genotyped with TaqMan (genotyping efﬁ-
ciency ¼ 99%; HWE p value ¼ 0.64). The ﬁnal analysis
therefore included 21 SNPs.
Genotype-Phenotype Associations
The number of cases needed to achieve 80% power at a ¼
0.05 for the SNPs studied varied widely, from 75 to 3111,
assuming a 1:2 ratio of cases versus controls (Table S1).
This range reﬂects the ORPR and minor allele frequencies
(MAFs) in cases and controls. Table S1 also presents the
number of cases needed assuming other ratios of cases
to controls, from 1:1 to 1:4. Increasing the number of
controls 4-fold resulted in a modest reduction, ~30%, of
the cases needed.
Figure 2 presents the calculated allelic OR and 95% CIs,
with the use of deﬁnite cases and controls and European
ancestry only. In addition to the results from BioVU data,
we plot the OR for the original GWAS result; subsequent
publications conﬁrming these results have very similar
values (data not shown). For example, the SNP
rs4506565 in TCF7L2 has previously been associated
with type 2 diabetes, with an ORPR of 1.37 and MAFs of
0.32 in cases and 0.39 in controls.24 To replicate this
ﬁnding assuming a similar genetic effect size, we would
need to identify 503 cases and 1006 controls. Genotyping
in subjects identiﬁed by the phenotype algorithms resulted
in 532 deﬁnite cases (MAF 0.35) and 886 controls (MAF
0.31), resulting in a calculated allelic OR of 1.29 (95% CI:
1.09–1.53; p ¼ 0.009; Table S4). The genotypic OR was
1.23 (1.05–1.45; p ¼ 0.006; Table S4). Homozygotes for
the minor (risk) allele had an OR of 1.7 (1.22–2.38; p ¼
0.0016) compared to homozygotes for the major allele or
heterozygotes. The results were very similar when the
553 cases and 1100 controls of European or unknown
ancestry were analyzed. Table 1 presents the results of all
allelic analyses, and Table S4 presents the genotypic anal-
yses, for both European and European þ unknown
ancestry, and for deﬁnite as well as deﬁnite þ probable
cases (rheumatoid arthritis and multiple sclerosis).
All 21 comparisons resulted in OR point estimates in the
expected direction, and for each of the ﬁve diseases studied,
at least one previously reported SNP association was
replicated (p < 0.05 for allelic OR). Two sets of SNPs in
type 2 diabetes were in LD with one another and, comfort-
ingly, showed similar results. The SNPs rs4506565,
rs1224332, and rs225537 (in or nearTCF7L2) have pairwise
r2 values of between 0.658 and 0.902; all three SNPs were
statistically signiﬁcantly associated with type 2 diabetes.
Similarly, rs5215 and rs5219 (in KCNJ11 [MIM 600937])
have a pairwise r2 of 0.994, and both were nonsigniﬁcant.
The analyses in Figure 2 are ordered by the number of cases
required for replication, and they show that the fewer cases
required, the greater the likelihood of replication with 95%
CIs of the point estimate not overlapping unity. When
fewer than 1000 cases were required, 8/12 associations
replicated in this fashion, whereas there was no replication
(0/9) of associations predicted to require more than 1000
cases. Similarly, a low ORPR implied that a large number of
cases would be required for replication: indeed, 8/14 associ-
ations with an ORPR > 1.25 replicated, in contrast to 0/7
with ORPR% 1.2.
Analyses that included the slightly larger numbers of
subjects whose ancestry was European or unknown yielded
the same results: replication of the same 8/14 associations
with ORPR > 1.25. When both deﬁnite and probable
cases for rheumatoid arthritis and multiple sclerosis were
included in the case series, one more association was repli-
cated in the rheumatoid arthritis set (Table 1).Discussion
We demonstrate here that common genetic variants asso-
ciated with disease can be replicated with the use of
samples from a DNA databank coupled to a deidentiﬁed
EMR, in effect rejecting the null hypothesis that EMR-
derived phenotypes are insufﬁciently distinct or detailed
to identify such associations that historically have been
observed in carefully characterized research cohorts. We
examined SNPs with a wide range of ORPR, from 1.14 to
2.36, and showed that the likelihood that we could repli-The Amcate any genotype-phenotype association in this set of
9483 records varied directly with the genetic effect size
of the previously reported association. These records
were selected because they were the ﬁrst accrued into the
resource and were accrued with no knowledge of under-
lying disease frequencies. The time required to generate
this set from which the cases and controls were identiﬁed
was only 4 mo.
Accruing, deﬁning, and accessing samples presented
multiple technical challenges, so establishing appropriate
quality-control checks was vital to the success of this
experiment and to use of any biorepository. Before geno-
typing and phenotyping, we validated sample-handling
algorithms by using gender testing, as previously re-
ported.14 A critical challenge was the deﬁnition of cases
and controls, both of which represent unique challenges
in the EMR and require nuanced application of informa-
tion-extraction techniques. It was not unusual to ﬁnd cases
in which a rheumatoid arthritis or multiple sclerosis code
from the International Statistical Classiﬁcation of Diseases
and Related Health Problems, revision 9 (ICD-9 code) was
associated with a clinic visit, only to have the diagnosis
subsequently overturned by a specialist consultation.
Thus, the case deﬁnitions each relied on both coded and
unstructured, free-text data, such as diagnoses, medica-
tions, or laboratory ﬁndings. Similarly, the criteria for
controls were not simply the absence of the condition,
but also included the absence of clinically similar condi-
tions and included documentation that the condition
was sought as well as absence of clinically similar condi-
tions. Assurance that controls do not have the disease is
especially important for relatively common diseases such
as diabetes, although it is potentially less impactful for
rare diseases such as multiple sclerosis. To avoid introduc-
tion of bias in our control populations by overly restrictive
criteria, these algorithms ensured that control subjects did
not have the case (or similar) diseases through clinic visits
with past medical history assessments, common labora-
tory values, and normal electrocardiograms.
The BioVU DNA Databank currently uses ancestry
assigned in administrative (e.g., billing) databases. The
9483 records analyzed included 77% European American,
11% African American, 1% Hispanic, 1% Asian, and 1%
other; an explicit statement of ancestry is absent in 9% of
records. Including the samples of unknown ancestry did
not alter the results, possibly because the majority of our
population is non-Hispanic European American. The accu-
racy of ancestry information contained in administrative
databases is unknown, although self-reported ancestry
agrees well with genetically determined race.28 Our current
evaluation of the ancestry of the ‘‘unknown’’ population of
BioVU indicates that the majority of these individuals are
European American (Ritchie et al., poster presented as part
of the Illumina Technology Workshops at the ASHG 59th
Annual Meeting, Honolulu, HI, USA, October 22, 2009).
Although EMR-based phenotyping can be complex, as
discussed above, the approach also has potentialerican Journal of Human Genetics 86, 560–572, April 9, 2010 563
Table 1. Allelic Odds Ratio
SNP
Cases Controls Cases Cases Controls Controls
N N
Minor Allele
Frequency
Minor
Allele
Minor Allele
Frequency
Minor
Allele
Allelic Chi-Square
p Value Odds Ratio
95% Confidence
Interval
ATRIAL FIBRILLATION
Ancestry: Non-Hispanic European; Case Definition: Definite
rs2200733 147 1439 0.1599 T 0.1120 T 0.0147 1.5093 (1.08–2.11)
rs10033464 143 1402 0.1084 T 0.0881 T 0.2530 1.2585 (0.85–1.87)
Ancestry: Non-Hispanic European þ Unknown; Case Definition: Definite
rs2200733 148 1467 0.1588 T 0.1115 T 0.0153 1.5048 (1.08–2.10)
rs10033464 144 1432 0.1111 T 0.0887 T 0.2066 1.2844 (0.87–1.90)
CROHN DISEASE
Ancestry: Non-Hispanic European; Case Definition: Definite
rs11805303 107 2884 0.3271 T 0.3017 T 0.4263 1.1253 (0.84–1.51)
rs17234657 106 2890 0.2028 G 0.1201 G 0.0003 1.8646 (1.32–2.63)
rs1000113 107 2905 0.0935 T 0.0730 T 0.2601 1.3096 (0.82–2.10)
rs17221417 107 2896 0.3785 G 0.2949 G 0.0086 1.4562 (1.10–1.93)
rs2542151 107 2901 0.1542 G 0.1649 G 0.6774 1.0834 (0.74–1.58)
Ancestry: Non-Hispanic European þ Unknown; Case Definition: Definite
rs11805303 110 3175 0.3288 T 0.3054 T 0.4557 1.1145 (0.84–1.45)
rs17234657 110 3182 0.1955 G 0.1204 G 0.0009 1.7756 (1.23–2.50)
rs1000113 111 3199 0.0946 T 0.0769 T 0.3323 1.2542 (0.79–1.98)
rs17221417 111 3188 0.3874 G 0.2917 G 0.0021 1.5353 (1.17–2.02)
rs2542151 111 3195 0.1577 G 0.1635 G 0.8158 1.0446 (0.72–1.51)
MULTIPLE SCLEROSIS
Ancestry: Non-Hispanic European; Case Definition: Definite
rs6897932 61 1861 0.2049 T 0.2515 T 0.2425 1.3036 (0.83–2.04)
rs3135388 61 1892 0.2887 T 0.1427 T <0.0001 2.3210 (1.55–3.48)
rs2104286 61 1888 0.2377 A 0.2582 A 0.6102 1.1163 (0.73–1.70)
Ancestry: Non-Hispanic European þ Unknown; Case Definition: Definite
rs6897932 88 2105 0.2045 T 0.2485 T 0.1855 1.2857 (0.89–1.87)
rs3135388 88 2139 0.2955 T 0.1431 T <0.0001 2.5120 (1.80–3.51)
rs2104286 88 2133 0.2102 A 0.2586 A 0.1503 1.3101 (0.91–1.89)
Ancestry: Non-Hispanic European; Case Definition: Definite þ Probable
rs6897932 68 1861 0.2132 T 0.2515 T 0.3118 1.2396 (0.82–1.88)
rs3135388 68 1892 0.2574 T 0.1427 T 0.0002 2.0818 (1.40–3.09)
rs2104286 68 1888 0.2279 A 0.2582 A 0.4275 1.1790 (0.78–1.77)
Ancestry: Non-Hispanic European þ Unknown; Case Definition: Definite þ Probable
rs6897932 96 2105 0.2083 T 0.2485 T 0.2072 1.2563 (0.88–1.79)
rs3135388 96 2139 0.2760 T 0.1431 T <0.0001 2.2840 (1.65–3.17)
rs2104286 96 2133 0.2083 A 0.2586 A 0.1190 1.3252 (0.93–1.89)
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Table 1. Continued
SNP
Cases Controls Cases Cases Controls Controls
N N
Minor Allele
Frequency
Minor
Allele
Minor Allele
Frequency
Minor
Allele
Allelic Chi-Square
p Value Odds Ratio
95% Confidence
Interval
RHEUMATOID ARTHRITIS
Ancestry: Non-Hispanic European; Case Definition: Definite
rs6679677 134 658 0.1194 A 0.1003 A 0.3496 1.2162 (0.81–1.83)
rs2476601 134 659 0.1194 A 0.1002 A 0.3454 1.2183 (0.81–1.84)
rs6457620 138 662 0.3370 T 0.4977 T <0.0001 1.9501 (1.49–2.56)
Ancestry: Non-Hispanic European þ Unknown; Case Definition: Definite
rs6679677 184 745 0.1141 A 0.0943 A 0.2609 1.2326 (0.86–1.78)
rs2476601 184 746 0.1141 A 0.0945 A 0.2576 1.2344 (0.86–1.88)
rs6457620 188 750 0.3601 T 0.4973 T <0.0001 1.6689 (1.33–2.09)
Ancestry: Non-Hispanic European; Case Definition: Definite þ Probable
rs6679677 210 658 0.1286 A 0.1003 A 0.1029 1.3235 (0.94–1.85)
rs2476601 210 659 0.1262 A 0.1002 A 0.1319 1.2975 (0.92–1.82)
rs6457620 214 662 0.3626 T 0.4977 T <0.0001 1.7422 (1.39–2.18)
Ancestry: Non-Hispanic European þ Unknown; Case Definition: Definite þ Probable
rs6679677 272 745 0.1250 A 0.0946 A 0.0459 1.3667 (1.00–1.86)
rs2476601 272 746 0.1232 A 0.0945 A 0.0589 1.3459 (0.99–1.83)
rs6457620 277 750 0.3776 T 0.4896 T <0.0001 1.6521 (1.35–2.02)
TYPE 2 DIABETES
Ancestry: Non-Hispanic European; Case Definition: Definite
rs4402960 527 877 0.3083 T 0.3079 T 0.9787 1.0023 (0.85–1.18)
rs10811661 534 887 0.1610 C 0.1753 C 0.3269 1.1074 (0.90–1.36)
rs4506565 532 886 0.3524 T 0.3053 T 0.0093 1.2384 (1.05–1.46)
rs12243326 520 876 0.3212 C 0.2785 C 0.0169 1.2253 (1.04–1.45)
rs12255372 510 847 0.3245 T 0.2816 T 0.0178 1.2257 (1.04–1.45)
rs5215 527 882 0.3672 C 0.3702 C 0.8728 1.0130 (0.86–1.19)
rs5219 533 888 0.3715 T 0.3705 T 0.9580 1.0042 (0.86–1.18)
rs8050136 533 886 0.4053 A 0.3916 A 0.4731 1.0584 (0.91–1.24)
Ancestry: Non-Hispanic European þ Unknown; Case Definition: Definite
rs4402960 548 1089 0.3139 T 0.3159 T 0.9067 1.0094 (0.86–1.18)
rs10811661 555 1103 0.1604 C 0.1727 C 0.3700 1.0931 (0.90–1.33)
rs4506565 553 1100 0.3535 T 0.3100 T 0.0117 1.2172 (1.04–1.42)
rs12243326 541 1088 0.3226 C 0.2845 C 0.0251 1.1976 (1.02–1.40)
rs12255372 530 1048 0.3236 T 0.2863 T 0.0305 1.1928 (1.02–1.40)
rs5215 547 1098 0.3656 C 0.3643 C 0.9404 1.0057 (0.87–1.17)
rs5219 554 1103 0.3700 T 0.3649 T 0.7728 1.0223 (0.88–1.19)
rs8050136 554 1102 0.4043 A 0.3897 A 0.4177 1.0628 (0.92–1.23)advantages. In some instances, the case diagnosis can be
ﬁrmer than that in prospective clinical trials or case-
control studies, because longitudinal information fromThe Ammultiple, interacting, trained physicians is available. For
example, differentiating Crohn disease from other condi-
tions such as ulcerative colitis beneﬁts from longitudinalerican Journal of Human Genetics 86, 560–572, April 9, 2010 565
Figure 2. Odds Ratios for Comparisons of Cases versus Controls for Each SNP Evaluated
These are ordered by the number of cases required for replication (‘‘number needed’’ column), calculated from the previously reported
odds ratio (ORPR, red square; see text). The blue diamonds indicate the point estimate of the allelic OR derived from the present analysis.
The error bars indicate the conﬁdence interval of the allelic OR derived from the present analysis. This analysis used only deﬁnite cases in
which European ancestry had been assigned. AF, atrial ﬁbrillation; CD, Crohn disease; MS, multiple sclerosis; RA, rheumatoid arthritis;
T2D, type 2 diabetes.information frommultiple, interacting, trained physicians
when available. Similarly, controls may also represent
a more deﬁnite phenotype than those in traditional
research cohorts because there is an average of 6.6 yrs of
follow up in the EMR. In our study, replication of geno-
type-phenotype associations was slightly improved by
incorporation of deﬁnite þ probable phenotypes in rheu-
matoid arthritis, but the sample sizes are small.
In this experiment, we did not replicate any association
with an ORPR < 1.25 or an estimated number of required
cases > 1000. Because it was undertaken early in the
growth of the biobank, the study was anticipated to be
underpowered to assess many of the analyses attempted,
given the prevalence of the diseases of interest in the ﬁrst
10,000 samples accrued. Our failure to replicate could
also have arisen because these associations could be impor-
tant only in certain populations. This highlights one of the
advantages of large DNA resources such as BioVU: simple
extrapolation indicates that with the current size of the
biobank, 18/21 tests of replication would be adequately
powered. It is noteworthy that the OR point estimates
for all 21 associations evaluated were in the expected direc-
tion. Larger populations may also permit discovery of new
genetic associations.566 The American Journal of Human Genetics 86, 560–572, April 9, 2However,we successfully replicatedgenotype-phenotype
associations that were underpowered. Although this could
reﬂect simple statistical variation for a few SNPs, it was
observed in multiple analyses for multiple diseases. It is
conceivable that that the phenotype criteria used here
result in amore stringently deﬁned case than in the original
studies that identiﬁed the genotype-phenotype associa-
tion. In addition, other studies have used controls drawn
from apparently healthy populations,16 and to the extent
that these include subjects who actually have disease, the
EMR-based approach that we have used may be superior.
It is alsopossible that the risk alleles are enriched in thepop-
ulation studied, although we observed this phenomenon
with multiple diagnoses. Studies in other data sets will be
required to address this issue and are a goal of the National
Human Genome Research Institute’s eMERGE Network.29
A long-term goal of BioVU and similar resources30 is to
provide a platform for evaluating and overcoming barriers
to incorporation of genomic and other high-dimensional
data into clinical medicine. One challenge is to determine
the added value of a particular genotype or set of genotypes
in clinical care. To address this question, data sets much
larger than those ordinarily accrued into clinical trials
may be required.31 Thus, EMR-based biobanks like BioVU010
may be not only useful but in fact indispensible in
advancing this ﬁeld. Moreover, as this experiment demon-
strates, EMR-based phenotyping can rapidly generate large
numbers of subjects across multiple diseases. Thus, the
approach that we describe ultimately provides a platform
for assessment and validation of genotype-phenotype
associations in clinical practice. In addition, the method
provides an opportunity to generate a closed loop: as
health care information accumulates, genotype-pheno-
type associations will become increasingly well deﬁned,
ultimately identifying common genotype variants that
are useful in clinical medicine.Table A1. ICD-9 and CPT Codes Used for Excluding Heart
Transplant
Description ICD-9/CPT Code
Heart replaced by transplant V42.01
Anesthesia for heart transplant or heart/lung
transplant
580
Complications of transplanted heart 996.83
Heart-lung transplant with recipient
cardiectomy-pneumonectomy
33935
Heart transplant, with or without recipient
cardiectomy
33945Appendix: Selection of Cases and Controls
General Approach
Phenotype-selection algorithms used a combination of
queries of structured billing codes and unstructured
‘‘natural language’’ clinical notes. Most algorithms com-
bined a search for disease codes taken from International
Classiﬁcation of Diseases, version 9-CM (ICD-9), and
procedure codes from Current Procedural Terminology
(CPT) billing records, with textual searches for medication
names used to treat the disease. For all text searches, we
included synonyms, abbreviations, acronyms, and com-
mon misspellings for all terms (including generic and
brand names for medications), assisted by standardized
vocabularies such as the Uniﬁed Medical Language
System (UMLS; see Web Resources) and natural language
processing tools such as the KnowledgeMap concept
identiﬁer.32
We required that control records have ‘‘minimum
content information,’’ deﬁned as an inpatient history and
physical admission document or comprehensive outpa-
tient clinic note that included nonempty medication and
past medical history sections.
We removed ‘‘family medical history’’ sections from all
clinical notes prior to processing.33
The algorithms considered inpatient admission notes,
progress notes, and discharge summaries; all outpatient
clinic notes (> 97% of all outpatient encounters produce
notes available in electronic formats since about 2001);
all problem lists (these include key diagnoses and proce-
dures, and allergy and medication lists); and the cardiolo-
gist-generated electrocardiogram (ECG) impressions.
For Crohn disease, many records included codes for
both ulcerative colitis and Crohn disease (e.g., a patient
initially thought to have ulcerative colitis who later has a
biopsy conﬁrming Crohn disease). To differentiate them,
the algorithm also used the ratio of billing codes for each
disease.
In each case, content experts were consulted to identify
potentially overlapping diseases (such as other autoim-
mune diseases for rheumatoid arthritis, Crohn disease,
and multiple sclerosis) that we excluded from both cases
and controls.The AmEach algorithm was validated and adjusted to achieve
target positive and negative predictive values, as described
in the text. The ﬁnal algorithms used to select cases and
controls are described in further detail below.Atrial Fibrillation
For all cases, we considered atrial ﬁbrillation and atrial
ﬂutter as similar entities. We excluded all patients who
had received heart transplants (identiﬁed by CPT codes;
Table A1).Deﬁnite cases: To identify deﬁnite cases, we required a cardi-
ologist diagnosis of atrial ﬁbrillation as identiﬁed by
a natural language processing tool from the unstructured
free text of the ‘‘ECG impression;’’ i.e., an ECGwith an ofﬁ-
cial interpretation of atrial ﬁbrillation. These were identi-
ﬁed by ﬁrst taking all ECG impressions (n ¼ 14,569) and
processing them with the KnowledgeMap concept identi-
ﬁer. This tool34 maps unstructured free text to standardized
biomedical concepts with their assertion or negation
status (e.g., ‘‘no atrial ﬁbrillation’’ becomes ‘‘C0004238
Atrial Fibrillation, status: negated’’ in which ‘‘C0004238’’
represents a unique identiﬁer for the concept of ‘‘atrial
ﬁbrillation’’ and its synonyms). There were only two
negated atrial ﬁbrillation or ﬂutter concepts, both in
records that had prior ECGs indicating atrial ﬁbrillation
(e.g., ‘‘compared with prior ECG, atrial ﬁbrillation has
resolved’’).
Controls: To be a control, a record had to meet all of the
conditions below:
d Contain at least one ECG whose impression does not
mention atrial ﬁbrillation (or synonym).
d Contain no ICD-9 codes representing atrial ﬂutter or
atrial ﬁbrillation (Table A2).
d Contain no free-text matches for atrial ﬁbrillation or
synonyms.
d Contain no free-text references (including synonyms)
to: direct-current cardioversion, atrial tachycardia or
multifocal atrial tachycardia, atrioventricular nodal
ablation.erican Journal of Human Genetics 86, 560–572, April 9, 2010 567
Table A2. ICD-9 Codes for Atrial Fibrillation or Atrial Flutter
Description ICD-9 Code
Atrial ﬁbrillation 427.31
Atrial ﬁbrillation and ﬂutter 427.3
Atrial ﬂutter 427.32
Table A3. Continued
Description ICD-9 Code
Sarcoidosis 135
Psoriasis and similar disorders 696
Psoriatic arthropathy 696.0
Other psoriasis and similar disorders 696.1
excluding psoriatic arthropathy
Other psoriasis and similar disorders 696.8
Reiter disease 099.3
Palindromic rheumatism 719.3
Ankylosing spondylitis 720.*
Thoracic spondylosis without myelopathy 721.2
Lumbosacral spondylosis without
myelopathy
721.3
Hashimoto thyroiditis 245.2
Toxic diffuse goiter 242.0
Myasthenia gravis 358.0*
Neonatal myasthenia gravis 775.2
Raynaud syndrome 443
Reiter disease 099.3
Multiple sclerosis 340
Demyelinating disease of the central nervous
system, unspeciﬁed
341.9
Irritable bowel disease 564.1
Ulcerative enterocolitis 556.*Crohn Disease
Deﬁnite cases: To be considered a deﬁnite case, a record had
to contain all of the following:
d At least one ICD-9 code for Crohn disease (555.*). If
also containing an ICD-9 code for ulcerative colitis
(556.*), we required that the ratio of Crohn disease
ICD-9 codes to ulcerative colitis ICD-9 codes wasR 2.
d At least one medication used to treat Crohn disease,
such as: balsalazide, mesalamine, sulfasalazine, cipro-
ﬂoxacin, levoﬂoxacin, metronidazole, rifaximin, pre-
dnisone, budesonide, azathioprine, mercaptopurine,
methotrexate, inﬂiximab, adalimumab, certolizumab,
natalizumab.
Controls: These were deﬁned as a record with ‘‘minimum
content information’’ described above, plus none of the
following:
d Any free-text references to key autoimmune diseases
or inﬂammatory bowel disease: rheumatoid arthritis,
Felty syndrome, juvenile arthritis, lupus, inﬂamma-
tory bowel disease, Crohn disease, ulcerative colitis,
reactive arthritis, sarcoidosis, ankylosing spondylitis,
Hashimoto thyroiditis, polymyositis, dermatomyosi-
tis, chronic lymphocytic thyroiditis, autoimmune
thyroid disease, Graves disease, Raynaud disease,
multiple sclerosis.
d ICD-9 codes indicating another autoimmune diseases
or inﬂammatory bowel disease (Table A3).Table A3. ICD-9 Codes Indicating Another Autoimmune Disease
or Inflammatory Bowel Disease
Description ICD-9 Code
Rheumatoid arthritis and other
inﬂammatory polyarthropathies
714.*
Discoid lupus erythematosus of eyelid 373.34
Lupus erythematosus 695.4
Systemic lupus erythematosus 710.0
Systemic sclerosis 710.1
Sjogren disease 710.2
Dermatomyositis 710.3
Polymyositis 710.4
Regional enteritis of small intestine 555.*
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Deﬁnite cases: To be considered a deﬁnite case, a record had
to meet one of the following two case deﬁnitions:
d Case deﬁnition 1: Presence of an ICD-9 code for
multiple sclerosis (340).
d Case deﬁnition 2: Any record matching all of the
following:010o One of the following ICD-9 codes: 341.9, demye-
linating disease of the central nervous system,
unspeciﬁed; 323.9, transverse myelitis.
o Any of the following medications: interferon-b 1a,
interferon-b 1b, glatiramer, natalizumab.
o Text match of ‘‘multiple sclerosis.’’
o No potentially overlapping autoimmune diseases
by ICD-9 code (Table A4).Possible cases: To be considered a possible case, a record had
to contain all of the following:
d Text match of ‘‘multiple sclerosis’’ in the clinical
record.
d Any one of the following ICD-9 codes: other demye-
linating diseases of central nervous system;
demyelinating disease of the central nervous system,
unspeciﬁed; optic neuritis.
d No potentially overlapping autoimmune diseases by
ICD-9 code (Table A4).
Because of the small number of cases of multiple sclerosis,
we manually reviewed all cases and analyzed them with
and without the autoimmune disease exclusions (those
with potentially overlapping autoimmune diseases were
referred to as ‘‘probable cases’’).Table A4. ICD-9 Codes Indicating Another Autoimmune Disease
Description ICD-9 Code
Rheumatoid arthritis and other
inﬂammatory polyarthropathies
714.*
Discoid lupus erythematosus of eyelid 373.34
Lupus erythematosus 695.4
Systemic lupus erythematosus 710.0
Systemic sclerosis 710.1
Sjogren disease 710.2
Dermatomyositis 710.3
Polymyositis 710.4
Regional enteritis of small intestine 555.*
Sarcoidosis 135
Psoriasis and similar disorders 696
Psoriatic arthropathy 696.0
Other psoriasis and similar disorders
excluding psoriatic arthropathy
696.1
Other psoriasis and similar disorders 696.8
Reiter disease 099.3
Palindromic rheumatism 719.3
Ankylosing spondylitis 720.*
Thoracic spondylosis without myelopathy 721.2
Lumbosacral spondylosis without
myelopathy
721.3
Hashimoto thyroiditis 245.2
Toxic diffuse goiter 242.0
Myasthenia gravis 358.0*
Neonatal myasthenia gravis 775.2
Raynaud syndrome 443
Table A5. ICD-9 Codes for Rheumatoid Arthritis
Description ICD-9 Code
Rheumatoid arthritis and other
inﬂammatory polyarthropathies
714
Rheumatoid arthritis 714.0
Felty syndrome 714.1
Other rheumatoid arthritis with visceral or
systemic involvement
714.2
Table A6. ICD-9 Codes Indicating Other Autoimmune Diseases
or Inflammatory Arthritides
Description ICD-9 Code
Reiter disease 099.3
Sarcoidosis 135
Toxic diffuse goiter 242.0
Hashimoto thyroiditis 245.0
Gouty arthropathy 274.0
Multiple sclerosis and other
demyelinating diseases
340, 341.9, 323.9
(Continued on next page)Controls: To be considered a control, a record had to
contain none of the following:
d Text match for the string ‘‘multiple sclerosis.’’
d A multiple sclerosis ICD-9 code (340, 341.8, 341.9, or
377.3).
d A multiple sclerosis medication.The Amd Any free-text references to key autoimmune diseases:
rheumatoid arthritis, Felty syndrome, juvenile rheu-
matoid arthritis, lupus, inﬂammatory bowel disease,
Crohn disease, ulcerative colitis, sarcoidosis, anky-
losing spondylitis, Hashimoto thyroiditis, reactive
arthritis, polymyositis, dermatomyositis, chronic lym-
phocytic thyroiditis, autoimmune thyroid disease,
Graves disease, Raynaud disease, multiple sclerosis.
Rheumatoid Arthritis
Deﬁnite cases: These were deﬁned as any record that met all
of the following criteria:
d Contains a rheumatoid arthritis ICD-9code (TableA5).d Contains a rheumatoid arthritis medication (any of
the following): methotrexate, sulfasalazine, minocy-
cline, hydroxychloroquine, adalimumab, etanercept,
inﬂiximab, gold, azathioprine, rituximab, anakinra,
abatacept, leﬂunomide.
d Contains a text match for ‘‘rheumatoid arthritis’’ in
any clinical note.
d Does not contain any of the following autoimmune
diseases or inﬂammatory arthritides, by ICD-9
code (Table A6) or by text match: juvenile rheumatoid
arthritis, inﬂammatoryosteoarthritis, reactive arthritis.
As with multiple sclerosis, we analyzed rheumatoid
arthritis cases with and without the autoimmune disease
exclusions. Those with potentially overlapping autoim-
mune diseases were referred to as ‘‘probable cases.’’erican Journal of Human Genetics 86, 560–572, April 9, 2010 569
Table A6. Continued
Description ICD-9 Code
Myasthenia gravis 358.0*, 775.2
Raynaud syndrome 443.0
Crohn disease 555.*
Ulcerative colitis 556.*
Irritable bowel syndrome 564.1
Lupus 695.4,710.0, 373.34
Psoriasis 696.*
Systemic sclerosis, Sjogren disease,
and polymyositis
710.1,710.2.
710.3, 710.4
Juvenile rheumatoid arthritis 714.3*
Osteoarthrosis 715.*
Palindromic rheumatism 719.*
Ankylosing spondylitis and other
spondylosis
720.*, 721.2, 721.3
Table A7. Continued
Description ICD-9 Code
Palindromic rheumatism 719.*
Ankylosing spondylitis and other spondylosis 720.*, 721.2, 721.3
Rheumatism, unspeciﬁed and ﬁbrositis 729.0Controls: These were deﬁned as any record that did not
contain any of the following:
d Any ICD-9 code for rheumatoid arthritis, autoim-
mune diseases, or other inﬂammatory arthritides
(Table A7).
Rheumatism, unspeciﬁed and ﬁbrositis 729.0Table A7. ICD-9 Code for Rheumatoid Arthritis, Autoimmune
Diseases, or Other Inflammatory Arthritides
Description ICD-9 Code
Reiter disease 099.3
Sarcoidosis 135
Toxic diffuse goiter 242.0
Hashimoto thyroiditis 245.0
Gouty arthropathy 274.0
Multiple sclerosis and other
demyelinating diseases
340, 341.9, 323.9
Myasthenia gravis 358.0*, 775.2
Raynaud syndrome 443.0
Crohn disease 555.*
Ulcerative colitis 556.*
Irritable bowel syndrome 564.1
Lupus 695.4, 710.0, 373.34
Psoriasis 696.*
Systemic sclerosis, Sjogren disease,
and polymyositis
710.1, 710.2.
710.3, 710.4
Rheumatoid arthritis and other inﬂammatory
polyarthropathies
714.*
Osteoarthrosis 715.*
570 The American Journal of Human Genetics 86, 560–572, April 9, 2d Any of the following text in clinical notes: lupus,
inﬂammatory bowel disease, Crohn disease, ulcera-
tive colitis, multiple sclerosis, transverse myelitis,
progressive systemic sclerosis, scleroderma, acroscle-
rosis, dermatomyositis, polymyositis, sarcoidosis,
psoriasis / psoriatic arthritis, arthritis, osteoarthritis /
degenerative joint disease, reactive arthritis, Sjogren
disease, rheumatism, ankylosing spondylitis, Hashi-
moto thyroiditis, chronic lymphocytic thyroiditis,
autoimmune thyroid disease, Graves disease, myas-
thenia gravis, Raynaud disease.
Type 2 Diabetes
We adapted the type 2 diabetes algorithm designed byWil-
liam Lowe, Abel Kho, and Wendy Wolf at Northwestern
University as part of the eMERGE Network to identify
patients at Vanderbilt. Notably, ~20% of the records identi-
ﬁed as type 2 diabetes cases also contained diagnostic codes
for type 1 diabetes. Manual review (described in the main
text) of 50of these cases revealed that allhad type2diabetes.
Deﬁnite cases:
d Any record including a type 2 diabetes ICD-9 code
(Table A8).
d A noninsulin hypoglycemic medication (Table A9).
Controls:
d No type 2 diabetes ICD-9 codes (Table A8).
d No impaired glucose ICD-9 codes (Table A9).
d No family history of diabetes (including type 1, type
2, or unspeciﬁed, as identiﬁed by keyword searches
of family history sections from clinical notes and
problem lists), because patients with a family history
of diabetes are more likely to develop diabetes in the
future (and thus end up being cases).
d No abnormal labs: glucose < 110 mg/dl, hemoglobin
A1c < 6.0%.Table A8. ICD-9 Codes Used for Defining Type 2 Diabetes Cases
Description ICD-9 Code
Diabetes II with other coma 250.30
250.32
Diabetes II with hyperosmolarity 250.20
250.22
010
Table A8. Continued
Description ICD-9 Code
Diabetes II with unspeciﬁed complication 250.90
250.92
Diabetes II with other unspeciﬁed manifestation 250.80
250.82
Diabetes II with peripheral circulatory disorder 250.70
250.72
Diabetes II with neurological manifestations 250.60
250.62
Diabetes II with ophthalmic manifestations 250.50
250.52
Diabetes II with renal manifestations 250.40
250.42
Diabetes II without mention of complication 250.00
250.02
Table A9. ICD-9 Code Exclusions for Type 2 Diabetes Controls
Description ICD-9 Code
Impaired fasting glucose 790.21
Impaired oral glucose tolerance test 790.22
Abnormal glucose, not otherwise speciﬁed 790.29
Glycosuria 791.5
Gestational diabetes 648.*
Dysmetabolic syndrome 277.7
Diabetes—asymptomatic 790.29
Diabetes (all) 250.*
Renal glycosuria 271.4Supplemental Data
Supplemental Data include four tables and can be found with this
article online at http://www.ajhg.org.Acknowledgments
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